D. Perroni

发表

Breast Cancer Estrogen and Progesterone Receptors: Associations with Patients' Clinical and Epidemiologic Characteristics

M. Indelli, A. Liberati, F. Parazzini, 1991, Tumori.

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis

O. Nanni, E. Scarpi, D. Amadori, 2008, Breast Cancer Research and Treatment.

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators.

M. Indelli, V. Torri, A. Liberati, 1994, JAMA.

Growth hormone and somatomedin behaviour in the newborn.

F. Minuto, D. Perroni, G. Giodano, 1976, Acta endocrinologica.

Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.

P. Zola, A. Bottini, L. Dogliotti, 1997, Anticancer research.

Phase II trial of continuous/metronomic 5-fluorouracil infusion plus long acting Octreotide in advanced neuroendocrine carcinoma

M. Brizzi, L. Dogliotti, L. Ciuffreda, 2007 .

Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients.

L. Dogliotti, D. Perroni, G. Grecchi, 1996, Lung cancer.

Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study.

O. Nanni, E. Scarpi, D. Amadori, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Neo-adjuvant chemotherapy].

G. Lauria, D. Perroni, G. Grecchi, 1988, Minerva chirurgica.

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.

P. Zola, A. Bottini, L. Dogliotti, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

M. Papotti, M. Brizzi, L. Dogliotti, 2009, BMC Cancer.